Prelude Therapeutics, Incorporated

Contributing Author

Recent Articles by Prelude Therapeutics, Incorporated

Nov-04	Prelude Therapeutics Announces Strategic Business Update PRLD GlobeNewswire
Nov-04	Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors PRLD GlobeNewswire
Nov-03	Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting PRLD GlobeNewswire
Oct-17	Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors PRLD GlobeNewswire
Aug-14	Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update PRLD GlobeNewswire
Jun-02	Prelude Therapeutics to Participate in Upcoming Healthcare Conferences PRLD GlobeNewswire
May-06	Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PRLD GlobeNewswire